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Objective: Epidemiological findings suggest a relationship between Alzheimer’s disease (AD), 94 
inflammation and dyslipidemia, although the nature of this relationship is not well understood. We 95 
investigated whether this phenotypic association arises from a shared genetic basis. 96 
Methods and Results: Using summary statistics (p-values and odds ratios) from genome-wide 97 
association studies of over 200,000 individuals, we investigated overlap in single nucleotide 98 
polymorphisms (SNPs) associated with clinically diagnosed AD and C-reactive protein (CRP), 99 
triglycerides (TG), high (HDL) and low-density lipoprotein (LDL) levels. We found up to 50-fold 100 
enrichment of AD SNPs for different levels of association with CRP, LDL, HDL and TG SNPs using 101 
an FDR threshold < 0.05. By conditioning on polymorphisms associated with the four phenotypes, we 102 
identified 55 loci associated with increased AD risk. We then conducted a meta-analysis of these 55 103 
variants across four independent AD cohorts (total n = 29,054 AD cases and 114,824 healthy 104 
controls) and discovered two genome-wide significant variants on chromosome 4 (rs13113697, 105 
closest gene HS3ST1, odds ratio (OR) = 1.07, 95% confidence interval (CI) = 1.05-1.11, p = 2.86 x 106 
10-8) and chromosome 10 (rs7920721, closest gene ECHDC3, OR = 1.07, 95% CI = 1.04-1.11, p = 107 
3.38 x 10-8). We also found that gene expression of HS3ST1 and ECHDC3 was altered in AD brains 108 
compared with control brains.   109 
Conclusions: We demonstrate genetic overlap between AD, CRP, and plasma lipids. By conditioning 110 
on the genetic association with the cardiovascular phenotypes, we identify novel AD susceptibility 111 
loci including two genome-wide significant variants conferring increased risk for Alzheimer’s disease.   112 
 113 
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Late-onset Alzheimer’s disease (AD) is the most common form of dementia with an estimated 118 
prevalence of 30 million people worldwide, a number that is expected to quadruple in the next 40 119 
years.1 Given the absence of disease-modifying therapies and increasing awareness that symptoms 120 
develop over many years, there is significant interest in identifying effective strategies for AD 121 
prevention. Delaying dementia onset by a modest 2 years could potentially lower the worldwide 122 
prevalence of AD by more than 22 million cases over the next 40 years, resulting in significant 123 
societal savings.1 124 
A growing body of evidence suggests an association between AD and potentially modifiable 125 
processes including dyslipidemia and inflammation. In observational studies, high serum cholesterol 126 
levels have been associated with increased risk of AD 2,3 and molecular 4 and biomarker findings 5 127 
suggest that phospholipids may play an integral role in modulating AD-associated pathogenesis. 128 
Complement factors and activated microglia are established histopathologic features in brains of AD 129 
patients 6 and epidemiological studies in older individuals indicate that high serum levels of 130 
inflammatory proteins are associated with cognitive decline 7 and may predict dementia risk. 8 131 
Genome-wide association studies (GWAS) in late-onset AD have replicated the established 132 
association with apolipoprotein E (APOE) and identified single nucleotide polymorphisms (SNPs) 133 
implicated in lipid metabolism, such as CLU and ABCA7 and inflammatory processes, such as CR1 134 
and HLA-DRB5. 9,10 In addition, a rare sequence variant in TREM-2 with known anti-inflammatory 135 
function has recently been identified as conferring increased risk for AD. 11,12 Taken together, these 136 
findings suggest that processes involved with lipid metabolism and inflammation may also impact 137 
Alzheimer’s pathogenesis.   138 
 5 
Combining GWAS from multiple disorders and phenotypes provides insights into genetic 139 
pleiotropy (defined as a single gene or variant being associated with more than one distinct 140 
phenotype) and could elucidate shared pathobiology. Using this approach, we have recently reported 141 
genetic overlap between a number of diseases and phenotypes and identified novel common variants 142 
associated with schizophrenia, 13,14 bipolar disorder,13  prostate cancer,15 hypertension, 16 and primary 143 
sclerosing cholangitis. 17 Here, we applied this method to AD, taking advantage of several large 144 
GWASs, 18-20 to identify SNPs associating with clinically diagnosed AD, C-reactive protein (CRP) 145 
levels, and plasma lipid levels (specifically triglycerides (TG), high- (HDL) and low-density 146 
lipoproteins (LDL)).  147 
 148 
METHODS 149 
Participant Samples 150 
We evaluated complete GWAS results in the form of summary statistics (p-values and odds ratios) 151 
for clinically diagnosed AD, 18 CRP levels, 19 and plasma lipid levels (TG, HDL and LDL 20 (see 152 
Table 1). The CRP GWAS summary statistic data consisted of 82,725 individuals drawn from 25 153 
studies with genotyped or imputed data at 2,671,742 SNPs (for additional details see reference 19). 154 
The plasma lipids GWAS summary statistic data consisted of 188,577 individuals with genotyped or 155 
imputed data at 2,508,375 SNPs (for additional details see reference 20). We obtained publicly 156 
available AD GWAS summary statistic data from the International Genomics of Alzheimer’s Disease 157 
Project (IGAP Stage 1 + 2, for additional details see Supplemental Information and reference 18). We 158 
used IGAP Stage 1 as our discovery cohort, which consisted of 17,008 AD cases (mean age = 74.7 ± 159 
7.7 years; 59.4% female) and 37,154 controls (mean age = 76.3 ± 8.1 years; 58.6% female) drawn 160 
from four different consortia across North America and Europe with genotyped or imputed data at 161 
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7,055,881 SNPs (for a description of the AD cases and controls within the IGAP Stage 1 sub-studies, 162 
please see reference 18). To confirm our findings from IGAP Stage 1, we assessed the p-values of 163 
pleiotropic SNPs (conditional FDR < 0.05; see Statistical analysis below) from the discovery analyses 164 
in three independent AD cohorts, namely the IGAP Stage 2 sample, a cohort of AD cases and 165 
controls drawn from the population of Iceland (deCODE), and a cohort of AD cases and controls 166 
drawn from the population of Norway (DemGene). The IGAP Stage 2 sample consisted of 8,572 AD 167 
cases (mean age = 72.5 ± 8.1 years; 61% female) and 11,312 controls (mean age = 65.5 ± 8.0 years; 168 
43.3% female) of European ancestry with genotyped data at 11,632 SNPs (for additional details see 169 
reference 18).  Clinical diagnosis of probable AD within the IGAP Stage 2 cohort was established 170 
according to the DSM-III-R and NINCDS-ADRDA criteria. 21 The deCODE dataset was drawn from 171 
the Icelandic population and included 2,470 genotyped AD cases (age = 84.9 ± 7.2 years; 65.8 % 172 
female) and 65,347 genotyped controls (age = 68.8 ± 13.7 years; 57.8% females) (for additional 173 
details see reference 12). As previously described, 12 patients from Iceland were diagnosed with 174 
definite, probable or possible Alzheimer’s disease based on the NINCDS-ADRDA criteria 21 or 175 
according to guidelines for ICD-10 F00, and were compared to population controls. The Norwegian 176 
sample (DemGene) included 1,004 cases (age = 74.1 ± 9.6 years; 60.2 % female) and 1,011 controls 177 
(age = 74.6 ± 9.3 years; 57.7 % female) with genotyped data at 693,377 SNPs. Clinical diagnosis of 178 
AD and dementia within the DemGene sample was established using ICD-10 research criteria 22, the 179 
recommendations from the National Institute on Aging-Alzheimer’s Association (NIA/AA) 23 or the 180 
NINCDS-ADRDA criteria 21 (Supplemental Information). The relevant institutional review boards or 181 
ethics committees approved the research protocol of the individual GWAS used in the current 182 
analysis, and all human participants gave written informed consent. 183 
 For gene expression analyses, we used publicly available total RNA expression data from 184 
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1647 autopsied brain tissues (from dorsolateral prefrontal cortex, visual cortex and cerebellum) in 185 
549 brains of 376 AD patients and 173 non-demented healthy controls from the Gene Expression 186 
Omnibus (GEO) data set GSE44772. 24 As described previously, 24 all subjects were diagnosed at 187 
intake and each brain underwent extensive neuropathology examination. Tissues were profiled on a 188 
custom-made Agilent 44K array of 40,638 DNA probes. 189 
 190 
Statistical analysis  191 
Using recently developed statistical methods to evaluate pleiotropic effects, 13-17 we evaluated SNPs 192 
associating with AD (discovery cohort - IGAP Stage 1) and CRP levels as well as AD and plasma 193 
lipid levels. For given associated phenotypes A and B, pleiotropic ‘enrichment’ of phenotype A with 194 
phenotype B exists if the proportion of SNPs or genes associated with phenotype A increases as a 195 
function of increased association with phenotype B. To assess for enrichment, we constructed fold-196 
enrichment plots of nominal –log10(p) values for all AD SNPs and for subsets of SNPs determined by 197 
the significance of their association with CRP and plasma lipids. We also utilized conditional 198 
quantile-quantile (Q-Q) plots, which are complementary to fold-enrichment plots and provide 199 
visualization of polygenic enrichment (for additional details see Supplemental Information). In fold-200 
enrichment plots, the presence of enrichment is reflected as an upward deflection of the curve for 201 
phenotype A if the degree of deflection from the expected null line is dependent on the degree of 202 
association with phenotype B. To assess for polygenic effects below the standard GWAS significance 203 
threshold, we focused the fold-enrichment plots on SNPs with nominal –log10(p) < 7.3 (corresponding 204 
to p > 5x10-8). The enrichment seen can be directly interpreted in terms of true discovery rate (TDR = 205 
1 – False Discovery Rate (FDR)) (for additional details see Supplemental Information).  206 
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To identify specific loci we computed conditional FDRs. 13,14 The standard FDR framework 207 
derives from a model that assumes the distribution of test statistics in a GWAS can be formulated as a 208 
mixture of null and non-null effects, with true associations (non-null effects) having more extreme 209 
test statistics, on average, than false associations (null effects). The FDR can be interpreted, as the 210 
probability that a SNP is null given its p-value is as small or smaller than its observed p-value. The 211 
conditional FDR is an extension of the standard FDR, which incorporates information from GWAS 212 
summary statistics of a second phenotype to adjust its significance level. The conditional FDR is 213 
defined as the probability that a SNP is null in the first phenotype given that the p-values in the first 214 
and second phenotypes are as small as or smaller than the observed ones. It is important to note that 215 
ranking SNPs by standard FDR or by p-values both give the same ordering of SNPs. In contrast, if 216 
the primary and secondary phenotypes are related genetically, conditional FDR re-orders SNPs, and 217 
results in a different ranking than that based on p-values alone. We used an overall FDR threshold of 218 
< 0.05, which means 5 expected false discovery per hundred reported. Additionally, we constructed 219 
Manhattan plots based on the ranking of conditional FDR to illustrate the genomic location. In all 220 
analyses, we controlled for the effects of genomic inflation by using intergenic SNPs (see 221 
Supplemental Information). Detailed information on fold enrichment and conditional Q-Q plots, 222 
Manhattan plots, and conditional FDR can be found in the Supplemental Information and prior 223 
reports. 13-17  224 
For loci with conditional FDR < 0.05, we performed a fixed effects, inverse variance weighted 225 
meta-analysis25 across all available AD cohorts (IGAP Stage 1 + 2, deCODE, and DemGene, total n = 226 
29,054 AD cases and 114,824 healthy controls) using the R package meta (http://CRAN.R-227 
project.org/package=meta).  Briefly, the fixed effects, inverse variance weighted meta-analysis 228 
summarizes the combined the statistical support across independent studies under the assumption of 229 
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homogeneity of effects.  Individual study β estimates (log odds ratios) are averaged, weighted by the 230 
estimated standard error. 26 The IGAP Stage 1+2 β estimates and standard errors were obtained from 231 
the publicly available summary statistics (for additional details, Online Methods and Supplementary 232 
Note within reference18).  For the DeCODE and DemGene cohorts, β estimates and standard errors 233 
were estimated via logistic regression implemented predicting AD case/control status from SNP risk 234 
alleles count. 235 
  For the gene expression analyses, we focused on transcript expression (total RNA levels) of 236 
genes closest (within 500 kB) to the SNPs reaching genome-wide significance in our meta-analysis. 237 
Using logistic regression, we examined whether transcript expression of these genes significantly 238 
differed between AD cases and controls. 239 
 240 
RESULTS 241 
We observed SNP enrichment for AD (IGAP Stage 1 – discovery cohort) across different levels of 242 
significance with CRP, TG, HDL and LDL levels indicating a genetic association between AD and 243 
the four cardiovascular phenotypes (Figure 1). For progressively stringent p-value thresholds for AD 244 
SNPs (i.e. increasing values of nominal –log10(p)), we found at least 50-fold enrichment using CRP, 245 
30-fold enrichment using TG, 20-fold enrichment using HDL and 40-fold enrichment using LDL 246 
(Figure 1). Conditional Q-Q plots similarly demonstrated polygenic enrichment in AD as a function 247 
of CRP and plasma lipids (Supplemental Figure 1).  248 
To identify AD-associated polymorphisms that are more likely to replicate, we ranked IGAP 249 
Stage 1 AD SNPs conditional on their genetic association with CRP and plasma lipids (conditional 250 
FDR). We restricted our analyses to SNPs found in both IGAP Stage 1 and 2 and focused on those 251 
AD variants that have not been previously described at a genome-wide significance. At a conditional 252 
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FDR < 0.05, we found 55 AD susceptibility loci from IGAP Stage 1 (Figure 2, Supplemental Table 1). 253 
For these 55 loci, we performed a meta-analysis across all available AD cohorts and found two novel 254 
genome-wide significant (p < 5 x 10-8) loci associated with increased risk for AD (Table 2). These 255 
two variants are: 1) rs13113697 (chromosome 4, closest gene HS3ST1, conditioning trait = TG, 256 
reference allele = T, OR = 1.07, 95% CI = 1.05-1.11, p = 2.86 x 10-8) (Figures 3a and 4a) and 2) 257 
rs7920721 (chromosome 10, closest gene ECHDC3, conditioning trait = TG, risk allele = G, OR = 258 
1.07, 95% CI = 1.04-1.11, p = 3.38 x 10-8) (Figures 3b and 4b).  259 
The meta-analysis also revealed three suggestive AD susceptibility loci with p-values < 1 x 260 
10-6 (Table 3). These three loci are rs7396366 (on chromosome 11, closest gene AP2A2, conditioning 261 
trait = CRP, reference allele = C, OR = 0.94, 95% CI = 0.92-0.96, p = 6.8 x 10-7), rs3131609 (on 262 
chromosome 15, closest gene USP50, conditioning trait = CRP, reference allele = C, OR = 0.93, 95% 263 
CI = 0.91-0.96, p = 7.21 x 10-7) and rs2526378 (on chromosome 17, closest gene BZRAP1, 264 
conditioning trait = TG, risk allele = G, OR = 0.94, 95% CI = 0.92-0.96, p = 2.73 x 10-7).  265 
We additionally evaluated the directionality of allelic effects in SNPs associated with AD and 266 
the four cardiovascular phenotypes (SNPs with conditional FDR < 0.05). Across all 55 shared loci, 267 
we found the same direction of effect between SNPs associated with AD and 1) CRP in 72% (18 out 268 
of 25, p-value = 0.02) 2) HDL in 40% (4 out of 10, p-value = 0.62), 3) LDL in 20% (1 out of 5, p-269 
value = 0.81), and 4) TG in 40% (6 out of 15, p-value = 0.69)  (Supplemental Table 1).  For HS3ST1 270 
and ECHD3 variants, we found an opposite direction of allelic effect between increased AD risk and 271 
TG levels (Supplemental Table 1). 272 
We assessed whether HS3ST1 and ECHD3 transcript levels are altered in AD brains compared 273 
with control brains (GEO dataset GSE 4472). We found significantly decreased HS3ST1 transcript 274 
expression (standardized -coefficient = -0.09201, standard error (SE) = 0.01864, p = 9.99 x 10-7) and 275 
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significantly increased ECHDC3 transcript expression (standardized -coefficient = 0.12715, SE = 276 
0.01829, p = 8.32 x 10-12) in AD brains compared with control brains. 277 
 278 
DISCUSSION 279 
In this study, we show that polymorphisms associated with CRP and plasma lipids (TG, HDL and 280 
LDL) are also associated with increased risk for AD (genetic pleiotropy). We found that genetic 281 
enrichment in AD based on SNP association with cardiovascular phenotypes results in improved 282 
statistical power for gene discovery. By conditioning on polymorphisms associated with CRP and 283 
plasma lipid levels, we identified 55 AD susceptibility loci. In meta-analyses across 4 independent 284 
cohorts, we found that two of these risk variants, namely rs13113697 (on chromosome 4, closest gene 285 
HS3ST1) and rs7920721 (on chromosome 10, closest gene ECHDC3), were genome-wide significant. 286 
We additionally observed that HS3ST1 and ECHDC3 transcript expression was different in AD brains 287 
compared with control brains.   288 
Our findings provide novel insights into the relationship between AD pathogenesis, 289 
inflammation and dyslipidemia, beyond the known loci associated with AD. We found a consistent 290 
direction of allelic effect between SNPs associated with AD risk and CRP levels indicating 291 
overlapping pathobiology between AD and inflammation. These results are consistent with the 292 
hypothesis that inflammatory mechanisms influence Alzheimer’s pathogenesis 9,27-28 and may have 293 
implications for treatment and prevention strategies in AD. On the other hand, we did not find a 294 
consistent direction of allelic effect between SNPs associated with AD risk and plasma lipid levels 295 
(LDL, HDL and TG). Additionally, for HS3ST1 and ECHD3 variants, we found an opposite direction 296 
of allelic effect between increased AD risk and TG levels. One hypothesis for these findings is that 297 
the observed pleiotropy between AD and plasma lipids could be due to different haplotypes/gene 298 
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alleles involving the same SNPs. Another equally plausible hypothesis is that the same 299 
haplotypes/gene alleles are involved for both AD and plasma lipids but the underlying biologic 300 
mechanisms are distinct. Based on these findings, it seems less likely the pleiotropic SNPs detected in 301 
this study influence AD pathogenesis via cholesterol mediated pathways.  302 
Unlike epidemiological studies, co-heritability analyses, 29 or bivariate GWAS methods, 30 303 
one strength of our current approach is the ability to detect genetic pleiotropy even when there is no 304 
correlation of the signed effects (mixed directionality of effect); the conditional FDR method can 305 
detect SNPs that have a non-null effect in one trait and that also tend to have a non-null effect in 306 
another trait, independent of directionality. Another strength of this framework is leveraging genetic 307 
signal in one phenotype to identify variants in a second phenotype that would otherwise not be 308 
detected using a single phenotype approach. We note that the conditional FDR approach allows for 309 
re-ordering (and re-ranking) of SNPs based on p-value significance in the second phenotype (e.g. 310 
CRP or TG) thus enabling identification of novel SNPs in the primary phenotype (e.g. AD). In 311 
addition, as previously demonstrated, these genetic analysis methods result in improved sensitivity 312 
for a given specificity. 13 Using this ‘pleiotropic’ approach, we detected 55 novel variants indicating 313 
that genetic enrichment improves statistical power for gene discovery. 314 
In meta-analyses, we discovered two GWAS significant AD susceptibility loci. The closest 315 
genes associated with the two risk variants showed altered RNA levels in postmortem AD brains 316 
compared with control brains suggesting a functional role. The first variant (rs13113697) is closest to 317 
the HS3ST1 gene on chromosome 4 (Figure 4a), which encodes heparan sulfate glucosaminyl 3-O-318 
sulfotransferase, an intraluminal Golgi protein enzyme with multiple biological activities. 31 The 319 
second variant (rs7920721) is closest to the ECHDC3 gene on chromosome 10 (Figure 4b), which 320 
encodes an enzyme called enoyl CoA hydratase domain containing 3. 32 We note that by conditioning 321 
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on cardiovascular traits and evaluating additional AD cohorts (deCODE and DemGene), we were 322 
able to find genome-wide significant evidence for previously18 suggested signal within HS3ST1 and 323 
ECHDC3. At p-value < 1.0 x 10-6, we additionally found three suggestive variants on chromosome 11 324 
(rs7396366, closest gene APA2A), chromosome 15 (rs3131609, closest gene USP50) and 325 
chromosome 17 (rs2526378, closest gene BZRAP1).  326 
It is important to note that in this study the diagnosis of AD was established clinically. Post-327 
mortem evidence from community and population based cohorts indicates that vascular brain injury 328 
often presents concomitantly with Alzheimer’s pathology and correlates with cognitive impairment 329 
above and beyond AD neuropathology. 33 It is feasible that the clinically diagnosed AD individuals 330 
from the IGAP, deCODE and DemGene cohorts may have concomitant vascular brain disease, which 331 
may further contribute to their cognitive decline and dementia. As such, an alternative interpretation 332 
of our findings is that the susceptibility loci identified in this study may increase brain vulnerability to 333 
vascular and/or inflammatory insults, which in turn may exacerbate the clinical consequences of AD 334 
pathological changes.  335 
In conclusion, we found polygenic overlap between AD, CRP and plasma lipids, and 336 
leveraged this association to identify three novel genome-wide significant variants associated with 337 
increased AD risk. Careful and considerable effort will be required to further characterize the novel 338 
candidate genes detected in this study and to detect the functional variants responsible for the 339 
association of these loci with Alzheimer’s risk. Although no single common variant maybe 340 
informative clinically, a combination of variants involved with inflammation or lipid metabolism may 341 
help identify older individuals at increased risk for AD. Our findings may also have implications for 342 
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FIGURE LEGENDS 557 
 558 
Figure 1.  Fold enrichment plots of enrichment versus nominal -log10 p-values (corrected for 559 
inflation) in Alzheimer’s disease (AD) below the standard GWAS threshold of p < 5x10-8 as a 560 
function of significance of association with C-reactive protein (CRP) (panel A), high-density 561 
lipoprotein (HDL) (panel B), low-density lipoprotein (LDL) (panel C), and triglycerides (TG) (panel 562 
D) at the level of -log10(p) ≥ 0, -log10(p) ≥ 1, -log10(p)  ≥ 2 corresponding to p ≤ 1, p ≤ 0.1, p ≤ 0.01, 563 
respectively. Blue line indicates all SNPs.  564 
 565 
Figure 2. ‘Conditional Manhattan plot’ of conditional –log10 (FDR) values for Alzheimer’s disease 566 
(AD) alone (IGAP Stage 1 AD cohort) (black) and AD given C-reactive protein (CRP; AD|CRP, 567 
green), triglycerides (TG; AD|TG, acquamarine), high-density lipoprotein (HDL, AD|HDL orange), 568 
and low-density lipoprotein (LDL; AD|LDL, red). SNPs with conditional –log10 FDR > 1.3 (i.e. FDR 569 
< 0.03) are shown with large points. A black line around the large points indicates the most 570 
significant SNP in each LD block and this SNP was annotated with the closest gene, which is listed 571 
above the symbols in each locus. For additional details, see Supplemental Information. 572 
 573 
Figure 3. Forest plots for a) rs13113697 on chromosome 4 and (b) rs7920721 on chromosome 10. 574 
 575 
Figure 4. Regional association plots for (a) rs13113697 on chromosome 4, and (b) rs7920721 on 576 
chromosome 10. Linkage Disequilibrium measured in the 1000 genomes European Populations using 577 
plink v1.07. 578 
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Table 2 New loci reaching genome-wide significance at conditional FDR < 0.05. Odds ratios provided for the major allele. 616 
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Table 3. SNPs showing suggestive association with AD at conditional FDR < 0.05. Odds ratios provided for the major allele. 619 
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International Genomics of Alzheimer's Project (IGAP) is a large two-stage study based 
upon genome-wide association studies (GWAS) on individuals of European ancestry. In 
stage 1, IGAP used genotyped and imputed data on 7,055,881 single nucleotide 
polymorphisms (SNPs) to meta-analyse four previously-published GWAS datasets 
consisting of 17,008 Alzheimer's disease cases and 37,154 controls (The European 
Alzheimer's disease Initiative – EADI the Alzheimer Disease Genetics Consortium – 
ADGC The Cohorts for Heart and Aging Research in Genomic Epidemiology consortium 
– CHARGE The Genetic and Environmental Risk in AD consortium – GERAD). In stage 
2, 11,632 SNPs were genotyped and tested for association in an independent set of 8,572 
Alzheimer's disease cases and 11,312 controls. Finally, a meta-analysis was performed 
combining results from stages 1 & 2. 
 
DemGene Cohort 
Patients were recruited from research cohorts in Norway as part of the nationwide 
DemGene Study, including samples from the HUKLI, DemVest, TrønderBrain, and 
AHUS case-control cohorts. Selection criteria and diagnostic procedures have been 
published for all cohorts.  These three studies had received approval from the relevant 
regional IRB, and all subjects provided written informed consent. The patients include in 
this study were all classified as mild cognitive impairment1 or AD according to the ICD-
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10 criteria, the recommendations from the National Institute on Aging-Alzheimer’s 
Association (NIA/AA) or the 1984 NINDS-ADRDA-criteria.  
Patients were diagnosed by trained specialists in neurology, geriatric medicine or 
psychiatry, all trained and experienced in diagnosing dementia. The diagnostic 
procedures differed slightly among centers, but all patients underwent a standardized 
comprehensive assessment program, which consisted of a medical history from the 
patient as well as a close family member, neuropsychological testing, a physical and 
psychiatric examination with the use of standardized assessment scales, blood sample 
analyses, and brain imaging. Cognitive assessment consisted of the MMSE global 
screening scale and a comprehensive battery of neuropsychological battery for memory, 
attention, executive and visuospatial functions and language. Standardized tests of 
depression and other neuropsychiatric symptoms were administered. Routine blood 
sample analysis and brain imaging was performed. In the different cohorts, either all or 
subgroups of patients had CSF Ab42, T-tau and P-tau AD biomarkers all analyzed at the 
same certified lab.   
 
Fold enrichment plots  
To assess genetic enrichment, we used fold enrichment plots conditional by ‘pleiotropic’ 
effects. For a given associated phenotype, enrichment for pleiotropic signals is present if 
the degree of deflection from the expected null line is dependent on SNP associations 
with the second phenotype. We constructed fold-enrichment plots of empirical quantiles 
of nominal –log10(p) values for SNP association with AD for all SNPs, and for subsets 
(strata) of SNPs determined by the nominal p-values of their association with CRP, TG, 
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HDL and LDL. Specifically, we computed the empirical cumulative distribution of 
nominal p-values for a given phenotype for all SNPs and for SNPs with significance 
levels below the indicated cut-offs for the other phenotypes (–log10(p) ≥ 0, –log10(p) ≥ 1, 
–log10(p) ≥2 corresponding to p < 1, p < 0.1, p < 0.01 respectively). The nominal p-values 
(–log10(p)) are plotted on the x-axis, and fold enrichment in the first phenotype as a 
function of the second phenotype is plotted on the x-axis (Figure 1). To assess for 
polygenic effects below the standard GWAS significance threshold, we focused the fold 
enrichment plots on SNPs with nominal –log10(p) < 7.3 (corresponding to p > 5x10
-8).  
 
Conditional Q-Q plots 
Q-Q plots compare a nominal probability distribution against an empirical distribution.  
In the presence of all null relationships, nominal p-values form a straight line on a Q-Q 
plot when plotted against the empirical distribution. For AD, CRP, TG, HDL and LDL 
SNPs and for each categorical subset (strata), -log
10 
nominal p-values were plotted 
against -log
10 
empirical p-values (conditional Q-Q plots, see Supplemental Figure 1). 
Deflections of the observed distribution from the projected null line reflect increased tail 
probabilities in the distribution of test statistics (z-scores) and consequently an over-
abundance of low p-values compared to that expected by chance (enrichment).  
Under large-scale testing paradigms, such as GWAS, quantitative estimates of 
likely true associations can be estimated from the distributions of summary statistics.2,3 
One common method for visualizing the enrichment of statistical association relative to 
that expected under the global null hypothesis is through Q-Q plots of nominal p-values 
obtained from GWAS summary statistics. The usual Q-Q curve has as the y-ordinate the 
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nominal p-value, denoted by “p”, and as the x-ordinate the corresponding value of the 
empirical cdf, denoted by “q”. Under the global null hypothesis the theoretical 
distribution is uniform on the interval [0,1]. As is common in GWAS, we instead plot -
log10 p against -log10 q to emphasize tail probabilities of the theoretical and empirical 
distributions. Therefore, genetic enrichment results in a leftward shift in the Q-Q curve, 
corresponding to a larger fraction of SNPs with nominal -log10 p-value greater than or 
equal to a given threshold. Conditional Q-Q plots are constructed by creating subsets of 
SNPs based on levels of an auxiliary measure for each SNP, and computing Q-Q plots 
separately for each level. If SNP enrichment is captured by variation in the auxiliary 
measure, this is expressed as successive leftward deflections in a conditional Q-Q plot as 
levels of the auxiliary measure increase. 
We constructed conditional Q-Q plots of empirical quantiles of nominal –log10(p) 
values for SNP association with AD for all SNPs, and for subsets (strata) of SNPs 
determined by the nominal p-values of their association with CRP, TG, HDL and LDL. 
Specifically, we computed the empirical cumulative distribution of nominal p-values for 
a given phenotype for all SNPs and for SNPs with significance levels below the indicated 
cut-offs for the other phenotypes (–log10(p) ≥ 0, –log10(p) ≥ 1, –log10(p) ≥2 corresponding 
to p < 1, p < 0.1, p < 0.01 respectively). The nominal p-values (–log10(p)) are plotted on 
the y-axis, and the empirical quantiles (–log10(q), where q=1-cdf(p)) are plotted on the x-
axis (Supplemental Figure 1). To assess for polygenic effects below the standard GWAS 
significance threshold, we focused the conditional Q-Q plots on SNPs with nominal –





The empirical null distribution in GWAS is affected by global variance inflation 
due to population stratification and cryptic relatedness 4 and deflation due to over-
correction of test statistics for polygenic traits by standard genomic control methods. 5 
We applied a control method leveraging only intergenic SNPs, which are likely depleted 
for true associations. 6 First, we annotated the SNPs to genic (5’UTR, exon, intron, 
3’UTR) and intergenic regions using information from the 1KGP. We used intergenic 
SNPs because their relative depletion of associations suggests that they provide a robust 
estimate of true null effects and thus seem a better category for genomic control than all 
SNPs. We converted all p-values to z-scores and for all phenotypes we estimated the 
genomic inflation factor λGC for intergenic SNPs.  We computed the inflation factor, λGC 
as the median z-score squared divided by the expected median of a chi-square 
distribution with one degree of freedom and divided all test statistics by λGC.  
 
 
Conditional True Discovery Rate (TDR)  
Enrichment seen in the fold enrichment plots can be directly interpreted in terms of TDR 
(equivalent to one minus the False Discovery Rate (FDR)). 7 We applied the conditional 
FDR method, 8 previously used for enrichment of GWAS based on linkage information. 9 
Specifically, for a given p-value cutoff, the FDR is defined as 
FDR(p) = π0F0(p) / F(p),  [1]    
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where π0 is the proportion of null SNPs, F0 is the null cdf, and F is the cdf of all SNPs, 
both null and non-null. Under the null hypothesis, F0 is the cdf of the uniform distribution 
on the unit interval [0,1], so that Eq. [1] reduces to 
FDR(p) = π0p / F(p),   [2]    
The cdf F can be estimated by the empirical cdf q = p / , where p is the number of 
SNPs with p-values less than or equal to p, and N is the total number of SNPs. Replacing 
F by q in Eq. [2], we get   
Estimated FDR(p) = π0p / q,  [3]    
which is biased upwards as an estimate of the FDR. 10 Replacing π0 in Equation [3] with 
unity gives an estimated FDR that is further biased upward;  
q* = p/q  [4] 
If π0 is close to one, as is likely true for most GWAS, the increase in bias from Eq. [3] is 
minimal. The quantity 1 – p/q, is therefore biased downward, and hence is a conservative 
estimate of the TDR. 
Referring to the formulation of the Q-Q plots, we see that q* is equivalent to the 
nominal p-value divided by the empirical quantile, as defined earlier.  Given the -log10 of 
the Q-Q plots we can easily obtain 
-log10(q*) = log10(q) – log10(p)  [5] 
demonstrating that the (conservatively) estimated FDR is directly related to the horizontal 
shift of the curves in the conditional Q-Q plots from the expected line x = y, with a larger 
shift corresponding to a smaller FDR, as illustrated in Supplemental Figure 1. As before, 
the estimated TDR can be obtained as 1-FDR. 
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Conditional statistics – test of association with AD 
To improve detection of SNPs associated with AD, we used a conditional FDR approach. 
Specifically, we conditioned AD SNPs based on p-values in a pleiotropic phenotype (e.g. 
CRP). We then assigned a conditional FDR value (denoted as FDR AD| CRP) for AD to 
each SNP, based on the combination of p-value for the SNP in AD and the pleiotropic 
trait (CRP), by interpolation into a 2-D look-up table. All SNPs with FDR < 0.01 (-
log10(FDR) > 2) in AD given CRP, TG, HDL and LDL are listed in Table 2 after 
‘pruning’ (removing all SNPs with r2 > 0.2 based on 1KGP linkage disequilibrium (LD) 
structure). A significance threshold of FDR < 0.01 corresponds to 1 false positive per 100 
reported associations. Pruned SNPs with FDR < 0.05 (-log10(FDR) > 1.3) in AD given 
CRP, TG, HDL and LDL are listed in Supplemental Table 1.  
 
Conditional FDR Manhattan plots 
To illustrate the localization of the genetic markers associated with AD given CRP, TG, 
HDL and LDL we used a ‘Conditional FDR Manhattan plot’, plotting all SNPs within an 
LD block in relation to their chromosomal location. As illustrated in Figure 2 within the 
main manuscript, the large points represent the SNPs with FDR < 0.05, whereas the small 
points represent the non-significant SNPs. All SNPs before ‘pruning’ (removing all SNPs 
with r2 > 0.2 based on 1KGP LD structure) are shown. The strongest signal in each LD 
block is illustrated with a black line around the circles. This was identified by ranking all 
SNPs in increasing order, based on the conditional FDR value for AD, and then removing 
SNPs in LD r2 > 0.2 with any higher ranked SNP. Thus, the selected locus was the most 
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significantly associated with AD in each LD block (Figure 2). Supplemental Figure 2 
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SUPPLEMENTAL FIGURE LEGENDS 
 
Supplemental Figure 1. Conditional Q-Q plots of nominal versus empirical -log10 p-
values (corrected for inflation) in Alzheimer’s disease (AD) using IGAP Stage 1 data 
below the standard GWAS threshold of p < 5x10-8 as a function of significance of 
association with C-reactive protein (CRP) (panel A), high-density lipoprotein (HDL) 
(panel B), low-density lipoprotein (LDL) (panel C), and triglycerides (TG) (panel D) at 
the level of -log10(p) ≥ 0, -log10(p) ≥ 1, -log10(p)  ≥ 2 corresponding to p ≤ 1, p ≤ 0.1, p ≤ 
0.01, respectively. Dotted lines in the conditional Q-Q plots indicate the null hypothesis.  
 
Supplemental Figure 2. Forest plots for the three suggestive AD susceptibility loci. 
These are a) rs7396366 on chromosome 11, (b) rs3131609 on chromosome 15, and (c) 


























Supplemental Table 1 All 65 novel AD susceptibility loci at conditional FDR < 0.05. Odds ratios provided for the major allele. 1 
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rs1148828 CADPS 3 C 4.74E-02 TG Diffe
rent 

































































































































































































































































































































































































































































































rs7920721 ECHDC3 10 G 4.49E-02 TG Diffe
rent 
2.89E-07 1.072 1.045-1.09 0.1239
68 






























































































































































































































































































































rs2526378 BZRAP1 17 G 1.83E-03 TG Diffe
rent 
























































































rs17656498 LIPG 18 C 3.97E-02 HDL Diffe 0.001431 0.95829 0.9320306- 0.6050 1.017 0.9541- 0.164 1.10123 0.9612 0.00975 0.9682 0.9447
 52 















rs4819996 CECR2 22 A 1.72E-02 LDL Diffe
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